SCOPUS 정보 검색 플랫폼

Journal of Infectious Diseases

Volumn 185, Issue SUPPL. 1, 2002, Pages

Biotechnology and clinical trials

(1) Siegel, Jay P a

a CENTER FOR DRUG EVALUATION AND RESEARCH (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BACTERIUM LIPOPOLYSACCHARIDE; CENTOXIN; FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

BIOTECHNOLOGY; CLINICAL RESEARCH; CONFERENCE PAPER; DRUG EFFICACY; GENE THERAPY; GOOD CLINICAL PRACTICE; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; SEPSIS;

ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; GENE THERAPY; HUMANS; MYOCARDIAL INFARCTION; ORNITHINE CARBAMOYLTRANSFERASE; ORNITHINE CARBAMOYLTRANSFERASE DEFICIENCY DISEASE; RESEARCH DESIGN; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0037083243 PISSN: 00221899 EISSN: None Source Type: Journal
DOI: 10.1086/338061 Document Type: Conference Paper

Times cited : (5)

References (25)

1
- 0026016470
- Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin
- (1991) N Engl J Med , vol.324 , pp. 429-436
- Ziegler, E.J.¹ Fisher Jr., C.J.² Sprung, C.L.³

2
- 0008237036
- FDA: Bethesda, MD, 4 September
- (1991) Transcripts of the open meeting of the vaccines and related biological products advisory - comments of J.P. Siegel

3
- 0026552353
- Anti-endotoxin monoclonal antibodies
- (1992) N Engl J Med , vol.326 , pp. 1153-1157
- Warren, H.S.¹ Danner, D.L.² Munford, R.S.³

4
- 0345206549
- Letter to the editor
- (1992) N Engl J Med , vol.327 , pp. 890-891
- Siegel, J.P.¹ Stein, K.E.² Zoon, K.C.³

5
- 0008237292
- Letter to the editor
- (1992) N Engl J Med , vol.327 , pp. 889-890
- Rosenfeld, S.¹

6
- 0028557981
- Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial
- (1994) Ann Intern Med , vol.121 , pp. 1-5
- McCloskey, R.V.¹ Straube, R.C.² Sanders, C.³

7
- 0022640774
- Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
- (1986) Lancet , vol.1 , pp. 397-401

8
- 0023805341
- Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
- (1988) Lancet , vol.2 , pp. 349-360

9
- 0023783508
- Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction (ASSET)
- (1988) Lancet , vol.2 , pp. 525-530
- Wilcox, R.G.¹ Von der Lippe, G.² Olsson, C.G.³ Jensen, G.⁴ Skene, A.M.⁵ Hampton, J.R.⁶

10
- 0022649225
- A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): Mortality, morbidity, and infarct size at 21 days
- (1986) N Engl J Med , vol.314 , pp. 1465-1471

11
- 0023835206
- Effects of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial
- (1988) Lancet , vol.1 , pp. 545-549

12
- 0020308864
- "Proving the null hypothesis" in clinical trials
- (1982) Control Clin Trials , vol.3 , pp. 345-353
- Blackwelder, W.C.¹

13
- 85014633198
- July
- (2000) ICH harmonised tripartite guidelines. Choice of control group in clinical trials

14
- 0034038179
- Equivalence and noninferiority trials
- (2000) Am Heart J , vol.139
- Siegel, J.P.¹

15
- 0033612881
- Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial
- (1999) Lancet , vol.354 , pp. 716-722

16
- 0028039957
- Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients
- (1994) Lancet , vol.343 , pp. 311-322

17
- 0008232249
- University of Pennsylvania, 3 March
- (2000) Letter to Institute for Human Gene Therapy

18
- 0008234340
- Title 21, US Code of Federal Regulations. Parts 50, 56 and 312

19
- 0001184885
- ICH harmonised tripartite guidelines. Guideline for good clinical practice
- May 1996
- (1997) Fed Regist , vol.62 , pp. 25691-25709

20
- 15044364965
- New initiatives to protect participants in gene therapy trials
- 7 March
- (2000) HHS News

21
- 0008197202
- Letter from JP Siegel, Center for Biologics Evaluation and Research, to sponsors of an IND or master file using or producing a gene therapy product. 6 March
- (2000)

23
- 0008192671
- Salewski JP, Bioresearch Monitoring Branch, CBER. 5 April
- (2001) Transcripts of the meeting of the Biological Response Modifiers Advisory Committee: overview of gene therapy surveillance inspections

24
- 0034648728
- Protecting research subjects - What must be done
- (2000) N Engl J Med , vol.343 , pp. 808-810
- Shalala, D.¹

25
- 0035819858
- Monitoring and ensuring safety during clinical research
- (2001) JAMA , vol.285 , pp. 1201-1205
- Morse, M.A.¹ Califf, R.M.² Sugarman, J.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.